The biosimilars market is estimated to reach USD 66.9 billion by 2028 from USD 29.4 billion in 2023, at a CAGR of 17.8% ...

The direct-to-consumer (DTC) platform – called Eliquis 360 Support – will offer Eliquis (apixaban) to patients who pay for ...

Pfizer has also ventured into the oncology biosimilars space and markets six biosimilars for cancer. Pfizer has also advanced its oncology clinical pipeline with several candidates entering late-stage ...

Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.

1. Pfizer can launch its Humira biosimilar in the U.S. on Nov. 20, 2023. In Europe, Pfizer can launch as soon as it receives European Medicines Agency approval. 2. Pfizer will pay royalties to AbbVie ...

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...

Sterile injectables and biosimilars are expected to be key drivers of Pfizer’s Essential Health business. Since late 2016, I have been bullish on Pfizer ( NYSE: PFE ).

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing. CNN values your feedback 1.

Pfizer said on Monday it has discontinued development of experimental weight-loss pill danuglipron after a trial patient experienced potential drug-induced liver injury that resolved after the ...